Revenue grew 8% year-over-year to €4.7 million, with strong liquidity and no debt. Major milestones included a public sector deal in Finland, U.S. lab expansion, and a new multi-omics research contract. The outlook targets at least 50% revenue growth this year.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.